https://www.selleckchem.com/pr....oducts/geldanamycin.
es to promote adequate physician review of OARs and image registrations to ensure the quality and safety of radiotherapy treatment plans. Pirfenidone is an antifibrotic agent that is potentially effective for the treatment of idiopathic pulmonary fibrosis (IPF). However, no study has reported on its prophylactic value against chemotherapy-associated acute IPF exacerbations when combined with chemotherapy for non-small cell lung cancer (NSCLC). The present study assessed the safety and effectiveness of pirfenidone combined with carb
Like
Comment
Share
